Abstract

Angioimmunoblastic T-cell lymphoma (AITL) is one of the commonest subtypes of peripheral T-cell lymphoma (PTCL) world-wide and the most common non-cutaneous PTCL in Western Europe. Despite aggressive chemotherapy +/- consolidation autologous stem cell transplant relapse occurs in >50% of cases which is either treated aggressively with high dose chemotherapy followed by allogeneic transplant or with therapy aimed at producing prolonged disease control.1 Biopsy of relapsed disease is essential as a subset may be complicated by a B-cell (often EBV+) lymphoproliferation. Histological progression may occur with a monomorphic/'tumour cell rich' appearance rather than the polymorphous appearance seen in typical AITL.2.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call